INTRODUCTION: Focal impulse and rotor modulation (FIRM) ablation can be used to target nonpulmonary vein (PV) sources of atrial fibrillation (AF). No published studies have compared freedom from atrial fibrillation (FFAF) after pulmonary vein reisolation (PVRI) plus FIRM to PVRI alone in patients with reconnected PVs undergoing repeat ablation. METHODS: A 3:1 matched retrospective cohort study was performed on 21 patients with recurrent AF and PV reconnection who underwent PVRI plus FIRM-guided ablation and 63 patients with recurrent AF treated with PVRI alone at a single institution. All patients in the PVRI-alone cohort had cryoballoon PVRI at the time of repeat ablation without additional lesion sets for AF. Cases were matched based on the type of AF (paroxysmal vs nonparoxysmal), left atrial diameter (±4 mm), left ventricular ejection fraction (±10%), duration of AF (±18 months), and age (±5 years). The primary endpoint was FFAF after a 3-month blanking period. RESULTS: Out of 53 total FIRM cases performed at Northwestern Memorial Hospital between 2015 and 2017, 21 patients had PVRI plus FIRM for recurrent AF with PV reconnection. These patients had an average of 3.3 ± 2.1 rotors (60% left atrial) ablated. Over a median follow-up time of 24.7 months (interquartile range, 13-36 months), patients in the PVRI-alone cohort demonstrated a higher rate of FFAF (n = 35; 55.6%) than patients in the PVRI plus FIRM-guided ablation cohort (n = 7; 33.3%) (logrank P = .049). CONCLUSION: In patients undergoing repeat ablation for AF with PV reconnection, PVRI plus FIRM did not increase FFAF compared to PVRI alone.
INTRODUCTION: Focal impulse and rotor modulation (FIRM) ablation can be used to target nonpulmonary vein (PV) sources of atrial fibrillation (AF). No published studies have compared freedom from atrial fibrillation (FFAF) after pulmonary vein reisolation (PVRI) plus FIRM to PVRI alone in patients with reconnected PVs undergoing repeat ablation. METHODS: A 3:1 matched retrospective cohort study was performed on 21 patients with recurrent AF and PV reconnection who underwent PVRI plus FIRM-guided ablation and 63 patients with recurrent AF treated with PVRI alone at a single institution. All patients in the PVRI-alone cohort had cryoballoon PVRI at the time of repeat ablation without additional lesion sets for AF. Cases were matched based on the type of AF (paroxysmal vs nonparoxysmal), left atrial diameter (±4 mm), left ventricular ejection fraction (±10%), duration of AF (±18 months), and age (±5 years). The primary endpoint was FFAF after a 3-month blanking period. RESULTS: Out of 53 total FIRM cases performed at Northwestern Memorial Hospital between 2015 and 2017, 21 patients had PVRI plus FIRM for recurrent AF with PV reconnection. These patients had an average of 3.3 ± 2.1 rotors (60% left atrial) ablated. Over a median follow-up time of 24.7 months (interquartile range, 13-36 months), patients in the PVRI-alone cohort demonstrated a higher rate of FFAF (n = 35; 55.6%) than patients in the PVRI plus FIRM-guided ablation cohort (n = 7; 33.3%) (logrank P = .049). CONCLUSION: In patients undergoing repeat ablation for AF with PV reconnection, PVRI plus FIRM did not increase FFAF compared to PVRI alone.
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Amr F Barakat; Oussama M Wazni; Walid I Saliba; Edlira Yzeiraj; Ram Amuthan; Karim Abdur Rehman; Khaldoun G Tarakji; Mohamed Bassiouny; Bryan Baranowski; Patrick Tchou; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Daniel Cantillon; Mohamed Kanj; Mina Chung; Bruce D Lindsay; Ayman A Hussein Journal: J Cardiovasc Electrophysiol Date: 2018-03-01
Authors: Roland Richard Tilz; Tina Lin; Andreas Rillig; Christian-H Heeger; Leonie Scholz; Peter Wohlmuth; Tudor Bucur; Andreas Metzner; Shibu Mathew; Erik Wissner; Feifan Ouyang; Karl-Heinz Kuck Journal: J Cardiovasc Electrophysiol Date: 2017-02-07
Authors: Hugo Enrique Coutiño; Carlo de Asmundis; Giacomo Mugnai; Darragh Moran; Valentina De Regibus; Erwin Ströker; Ken Takarada; Diego Ruggiero; Rajin Choudhury; Stefan Beckers; Carla Van Gompel; Jan Poelaert; Saverio Iacopino; Pasquale Filannino; Pedro Brugada; Gian-Battista Chierchia Journal: J Interv Card Electrophysiol Date: 2016-08-25 Impact factor: 1.900
Authors: John M Miller; Robert C Kowal; Vijay Swarup; James P Daubert; Emile G Daoud; John D Day; Kenneth A Ellenbogen; John D Hummel; Tina Baykaner; David E Krummen; Sanjiv M Narayan; Vivek Y Reddy; Kalyanam Shivkumar; Jonathan S Steinberg; Kevin R Wheelan Journal: J Cardiovasc Electrophysiol Date: 2014-07-23
Authors: Junaid A B Zaman; Tina Baykaner; Paul Clopton; Vijay Swarup; Robert C Kowal; James P Daubert; John D Day; John Hummel; Amir A Schricker; David E Krummen; Moussa Mansour; Gery F Tomassoni; Kevin R Wheelan; Mohan Vishwanathan; Shirley Park; Paul J Wang; Sanjiv M Narayan; John M Miller Journal: JACC Clin Electrophysiol Date: 2017-04
Authors: Emilio Osorio-Jaramillo; James L Cox; Sarah Klenk; Alexandra Kaider; Philipp Angleitner; Paul Werner; Andreas Strassl; Markus Mach; Guenther Laufer; Marek P Ehrlich; Niv Ad Journal: Front Cardiovasc Med Date: 2022-09-29
Authors: Graham Peigh; Jeremiah Wasserlauf; Kelly Vogel; Rachel M Kaplan; Anna Pfenniger; Daniel Marks; Arjun Mehta; Alexandru B Chicos; Rishi Arora; Susan Kim; Albert Lin; Nishant Verma; Kaustubha D Patil; Bradley P Knight; Rod S Passman Journal: J Cardiovasc Electrophysiol Date: 2021-07-05 Impact factor: 2.942